Skip to content
Screener

Glaukos GKOS Pre-Tax Income

Pre-Tax Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.75B+3.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.53B+0.6%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
-$4.42M+62.9%
AbbVie logo
AbbVieABBV
$4.28B+175%
Schering-Plough logo
Schering-PloughSGP
-$13.82M-56.6%
Bausch + Lomb logo
Bausch + LombBLCO
-$11M+92.5%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest expense(1,459)(1,151)(2,584)(2,314)
Other (expense) income, net(1,274)1,857(2,023)2,802
Total non-operating (expense) income(454)3,2801036,138
Loss before taxes(17,721)(19,409)(37,020)(37,229)
Income tax provision6562481,140574
Net loss$(18,377)$(19,657)$(38,160)$(37,803)
Basic and diluted net loss per share$(0.31)$(0.34)$(0.65)$(0.66)
Weighted-average shares outstanding used to compute basic and diluted net loss per share58,81857,20558,41956,922

Item 1. Financial Statements

FAQ

What is Glaukos's pre-tax income?
Glaukos (GKOS) reported pre-tax income of -$17.72M in Q2 2026.
How has Glaukos's pre-tax income changed year-over-year?
Glaukos's pre-tax income increased by 8.7% year-over-year, from -$19.41M to -$17.72M.
What is the long-term trend for Glaukos's pre-tax income?
Over 4 years (2021 to 2025), Glaukos's pre-tax income has grown at a 40.7% compound annual growth rate (CAGR), from -$49.27M to -$193.04M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Glaukos's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude